Skip to main content
Figure 3 | Journal of Neuroinflammation

Figure 3

From: Anti-inflammatory effects of BHBA in both in vivo and in vitro Parkinson’s disease models are mediated by GPR109A-dependent mechanisms

Figure 3

Effects of β-hydroxybutyric acid (BHBA) treatment on the levels of dopamine (DA) and 3,4-dihydroxyphenylacetic acid (DOPAC) in the striatum. Rats were randomly grouped and then pretreated with BHBA (0.4, 0.8, or 1.6 mmol/kg/d) or vehicle 3 days before lipopolysaccharide (LPS) injection and subsequently for 21 days after LPS injection (24 days in total). The levels of DA (A) and DOPAC (B) in the striatum were detected by high-performance liquid chromatography (HPLC), and the ratio of the right to left side was calculated. The results are expressed as the mean ± SD. *P <0.05 and **P <0.01 compared with the LPS-treated rats; and ## P <0.01 compared with the sham-operated control rats.

Back to article page